Bioversys secures USD 6 million investment to advance clinical program in China

12.09.2024 12:34, Rita Longobardi

Bioversys has secured USD 6 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund to support the clinical development of its antibacterial drug, BV100, in China. The trials, set to begin in early 2025, will target infections caused by multi-drug resistant bacteria, positioning the company for a global Phase 3 study.

BioVersys is a clinical-stage biopharmaceutical company developing novel antibacterial products to treat life-threatening infections caused by multi-drug resistant (MDR) bacteria. Their lead program, BV100, targets carbapenem-resistant Acinetobacter baumannii (CRAB), a top-priority pathogen for the WHO and CDC, responsible for high ICU mortality rates.

CRAB resistance has surged in China, with rates rising from 32% in 2005 to over 75% in 2018. BioVersys plans to launch a Phase 1 study in China by early 2025, followed by a global Phase 3 trial.

The Guangzhou Sino-Israel Bio-Industry Investment Fund (GIBF) has invested USD 6M in BioVersys to support these trials. GIBF's expertise and network will help accelerate BV100’s development and commercialization in China, including support for multi-center trials and regulatory approvals.

BioVersys participated in Venture Leaders China in 2016, was ranked among the TOP 100 Swiss Startups from 2011 to 2013, won the final stage of Venture Kick, participated in Venture Leaders Technology in 2008 and in the SIX IPO Academy.
 

"As a scientific founder, the educational programs that are organized and co-organized by Venturelab, such as the SIX IPO Academy, provide very valuable toolboxes that you need during your entrepreneurial path," stated Marc Gitzinger, Co-Founder and CEO of BioVersys. "Funny annecdote: During one of the kickers camps was my first outreach to our now long term partner GSK... talking impact of Venture Kick. "

CSO Sergio Lociuro, CEO Marc Gitzinger, and Chief Development Officer Glenn Dale